Endothelin-3 is produced by metastatic melanoma cells and promotes melanoma cell survival

Journal of Cutaneous Medicine and Surgery

Volumn 12, Issue 2, 2008, Pages 64-70

  Tang, Liren ^a,b,c,d,e   Su, Mingwan ^a,b,c,d,e   Zhang, Yi ^a,b,c,d,e   Ip, Wency ^a,b,c,d,e   Martinka, Magdalena ^a,b,c,d,e   Huang, Changzheng ^a,b,c,d,e   Zhou, Youwen ^a,b,c,d,e  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER COASTAL HEALTH RESEARCH INSTITUTE   (Canada)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d ANHUI MEDICAL UNIVERSITY   (China)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN 2; ENDOTHELIN 3; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA;

ARTICLE; CELL CULTURE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MELANOMA CELL; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SKIN BIOPSY; UPREGULATION; BIOSYNTHESIS; GENE EXPRESSION REGULATION; MELANOCYTE; MELANOMA; METABOLISM; METASTASIS; NEVUS; PHYSIOLOGY; SKIN TUMOR; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL SURVIVAL; ENDOTHELIN-3; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOCYTES; MELANOMA; NEVUS; RNA, MESSENGER; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 46749136931     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2008.06164     Document Type: Article

References (51)

1. Arai H, Hori S, Aramori I, et al. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990;348:730-2.
2. Hemsen A, Lundberg JM. Presence of endothelin-1 and endothelin-3 in peripheral tissues and central nervous system of the pig. Regul Pept 1991;36:71-83.
3. Levin ER. Endothelins. N Engl J Med 1995;333:356-63.
4. Brand M, Le Moullec JM, Corvol P, et al. Ontogeny of endothelins-1 and -3, their receptors, and endothelin converting enzyme-1 in the early human embryo. J Clin Invest 1998;101:549-59.
5. Ali H, Dashwood M, Dawas K, et al. Endothelin receptor expression in colorectal cancer. J Cardiovasc Pharmacol 2000; 36(5 Suppl 1):S69-71.
6. Bagnato A, Natali PG. Targeting endothelin axis in cancer. Cancer Treat Res 2004;119:293-314.
7. Donckier J, Michel L, Delos M, et al. Endothelin axis expression in medullary thyroid carcinoma: a potential therapeutic target. Clin Endocrinol (Oxf) 2004;61:282-4.
8. Douglas ML, Richardson MM, Nicol DL, Endothelin axis expression is markedly different in the two main subtypes of renal cell carcinoma. Cancer 2004;100:2118-24.
9. Nelson J, Bagnato A, Battistini B, et al. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003;3:110-6.
10. Opdecamp K, Kos L, Amheiter H, et al. Endothelin signalling in the development of neural, crest-derived melanocytes. Biochem Cell Biol 1998;76:1093-9.
11. Hirata Y. Endothelin peptides. Curr Opin Nephrol Hypertens 1996;5:12-5.
12. Kurihara M, Ochi A, Kawaguchi T, et al. Localization and characterization of endothelin receptors in human gliomas: a growth factor? Neurosurgery 1990;27:275-81.
13. Baynash AG, Hosoda K, Giaid A, et al. Interaction of endothelin-3 with endothelin-B receptor is essential for development of epidermal melanocytes and enteric neurons. Cell 1994;79:1277-85.
14. Kurihara H, Kurihara Y, Nagai R, et al. Endothelin and neural crest development. Cell Mol Biol (Noisy-le-grand) 1999;45:639-51.
15. Lahav R, Dupin E, Lecoin L, et al. Endothelin 3 selectively promotes survival and proliferation of neural crest-derived glial and melanocytic precursors in vitro. Proc Natl Acad Sci U S A 1998;95:14214-9.
16. Nataf V, Le Douarin NM. Induction of melanogenesis by tetradecanoylphorbol-13 acetate and endothelin 3 in embryonic avian peripheral nerve cultures. Pigment Cell Res 2000;13:172-8.
17. Dupin E, Glavieux C, Vaigot P, et al. Endothelin 3 induces the reversion of melanocytes to glia through a neural crest-derived glial-melanocytic progenitor. Proc Natl Acad Sci U S A 2000;97: 7882-7.
18. Dupin E, Le Douarin NM. Development of melanocyte precursors from the vertebrate neural crest. Oncogene 2003;22:3016-23.
19. Kenny SE, Hofstra RM, Buys CH, et al. Reduced endothelin-3 expression in sporadic Hirschsprung disease. Br J Surg 2000;87: 580-5.
20. Robertson K, Mason I, Hall S. Hirschsprung's disease: genetic mutations in mice and men. Gut 1997;41:436-41.
21. Gohji K, Kitazawa S, Tamada H, et al. Expression of endothelin receptor A associated with prostate cancer progression. J Urol 2001;165:1033-6.
22. Le Brun G, Aubin P, Soliman H, et al. Upregulation of endothelin 1 and its precursor by IL-1beta, TNF-alpha, and TGF-beta in the PC3 human prostate cancer cell line. Cytokine 1999;11:157-62.
23. Nelson JB, Carducci MA. The role of endothelin-1 and endothelin receptor antagonists in prostate cancer. BJU Int 2000;85 Suppl 2:45-8.
24. Nelson JB, Chan-Tack K, Hedican SP, et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996;56:663-8.
25. Del Bufalo D, Di Castro V, Biroccio A, et al. Endothelin-1 acts as a survival factor in ovarian carcinoma cells. Clin Sci (Lond) 2002;103 Suppl 48:302S-5S.
26. Del Bufalo D, Di Castro V, Biroccio A, et al. Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol Pharmacol 2002;61:524-32.
27. Rosano L, Salani D, Di Castro V, et al. Endothelin-1 promotes proteolytic activity of ovarian carcinoma. Clin Sci (Lond) 2002;103 Suppl 48:306S-9S.
28. Rosano L, Varmi M, Salani D, et al. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res 2001;61:8340-6.
29. Salani D, Di Castro V, Nicotra MR, et al. Role of endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol 2000;157: 1537-47.
30. Spinella F, Rosano L, Di Castro V, et al. Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. J Biol Chem 2004;279:46700-5.
31. Spinella F, Rosano L, Di Castro V, et al. Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells. J Biol Chem 2002;277: 27850-5.
32. Arun C, DeCatris M, Hemingway DM, et al. Endothelin-1 is a novel prognostic factor in non-small cell lung cancer. Int J Biol Markers 2004;19:262-7.
33. Kusuhara M, Yamaguchi K, Nagasaki K, et al. Production of endothelin in human cancer cell lines. Cancer Res 1990;50:3257-61.
34. Bagnato A, Cirilli A, Salani D, et al. Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade. Cancer Res 2002;62:6381-4.
35. Alonso SR, Ortiz P, Pollan M, et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 2004;164:193-203.
36. Bagnato A, Rosano L, Spinella F, et al. Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression. Cancer Res 2004;64:1436-43.
37. Boukerche H, Su ZZ, Kang DC, et al. Identification and cloning of genes displaying elevated expression as a consequence of metastatic progression in human melanoma cells by rapid subtraction hybridization. Gene 2004;343:191-201.
38. Smith SL, Damato BE, Scholes AG, et al. Decreased endothelin receptor B expression in large primary uveal melanomas is associated with early clinical metastasis and short survival. Br J Cancer 2002;87:1308-13.
39. Yohn JJ, Smith C, Stevens T, et al. Human melanoma cells express functional endothelin-1 receptors. Biochem Biophys Res Commun 1994;201:449-57.
40. Watanabe K, Hiraki H, Hasegawa H, et al. Immunohistochemical localization of endothelin-1, endothelin-3 and endothelin receptors in human pheochromocytoma and paraganglioma. Pathol Int 1997;47:540-6.
41. Lahav R, Suva ML, Rimoldi D, et al. Endothelin receptor B inhibition triggers apoptosis and enhances angiogenesis in melanomas. Cancer Res 2004;64:8945-53.
42. Carducci MA, Nelson JB, Bowling MK, et al. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol 2002;20:2171-80.
43. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21:679-89.
44. Jimeno A, Carducci M. Atrasentan: targeting the endothelin axis in prostate cancer. Expert Opin Investig Drugs 2004;13:1631-40.
45. Eberle J, Weitmann S, Thieck O, et al. Downregulation of endothelin B receptor in human melanoma cell lines parallel to differentiation genes. J Invest Dermatol 1999;112:925-32.
46. Kikuchi K, Nakagawa H, Kadono T, et al. Decreased ET(B) receptor expression in human metastatic melanoma cells. Biochem Biophys Res Commun 1996;219:734-9.
47. Eberle J, Fecker LF, Orfanos CE, et al. Endothelin-1 decreases basic apoptotic rates in human melanoma cell lines. J Invest Dermatol 2002;119:549-55.
48. Lahav R, Heffner G, Patterson PH. An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc Natl Acad Sci U S A 1999;96:11496-500.
49. Zhou Y, Dai DL, Martinka M, et al. Osteopontin expression correlates with melanoma invasion. J Invest Dermatol 2005;124: 1044-52.
50. Harpio R, Einarsson R. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem 2004;37: 512-8.
51. Demunter A, De Wolf-Peeters C, Degreef H, et al. Expression of the endothelin-B receptor in pigment cell lesions of the skin. Evidence for its role as tumor progression marker in malignant melanoma. Virchows Arch 2001;438:485-91.